{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ExoFlo",
            "NStudiesAvail": 430108,
            "NStudiesFound": 9,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 9,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "To evaluate the safety and efficacy of intravenous(IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles(EV), ExoFlo, as treatment for Acute Respiratory Distress Syndrome."
                        ],
                        "BriefTitle": [
                              "Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS"
                        ],
                        "CentralContactEMail": [
                              "hmoran@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Heidi Moran"
                        ],
                        "CentralContactPhone": [
                              "800-791-1021"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "January 2023"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "ARDS, Human"
                        ],
                        "ConditionAncestorId": [
                              "D000008171",
                              "D000012140",
                              "D000012120"
                        ],
                        "ConditionAncestorTerm": [
                              "Lung Diseases",
                              "Respiratory Tract Diseases",
                              "Respiration Disorders"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC23",
                              "All",
                              "BC08",
                              "BC16",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 2,
                        "BriefSummary": [
                              "Protocol Summary\n\nTitle: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory Crohn's disease.\nShort Title: ExoFlo for Crohn's Disease\nPhase: 1\nMethodology: Open label\nStudy Duration: 24 months\nSubject Participation: 70 weeks\nSingle or Multi-Site: Single site\n\nPrimary Objectives:\n\nTo evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\n\nSecondary Objectives:\n\nTo evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.\n\nTo evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.\n\nNumber of Subjects: 10\nDiagnosis and Main Inclusion Criteria: Subjects must have colitis, ileitis, or ileocolitis previously confirmed at any time in the past by radiography, histology, and/or endoscopy, and must allow a 8-week washout for prior TNF antagonist use.\nStudy Product, Dose, Route, Regimen:\n\nArm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).\n\nArm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15).\n\nStatistical Methodology: This is a safety study with exploratory assessment of efficacy. The study has insufficient power to confirm efficacy. All assessments of efficacy will be exploratory for the purpose of hypothesis-generation in larger sample sizes."
                        ],
                        "BriefTitle": [
                              "A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease"
                        ],
                        "CentralContactEMail": [
                              "sascha@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Sascha Sengupta, MD"
                        ],
                        "CentralContactPhone": [
                              "512-387-3685"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "March 1, 2024"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Crohn Disease",
                              "IBD - Irritable Bowel Disease"
                        ],
                        "ConditionAncestorId": [
                              "D000015212",
                              "D000005759",
                              "D000005767",
                              "D000004066",
                              "D000003109",
                              "D000003108"
                        ],
                        "ConditionAncestorTerm": [
                              "Inflammatory Bowel Diseases",
                              "Gastroenteritis",
                              "Gastrointestinal Diseases",
                              "Digestive System Diseases",
                              "Colonic Diseases, Functional",
                              "Colonic Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC06",
                              "All",
                              "BC23"
                        ],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 3,
                        "BriefSummary": [
                              "Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19)\n\nTo evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles, ExoFlo, as treatment for mild-moderate COVID-19."
                        ],
                        "BriefTitle": [
                              "Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial"
                        ],
                        "CentralContactEMail": [
                              "hmoran@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Heidi Moran"
                        ],
                        "CentralContactPhone": [
                              "800-791-1021"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "March 7, 2023"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "COVID-19"
                        ],
                        "ConditionAncestorId": [
                              "D000012141",
                              "D000007239",
                              "D000011024",
                              "D000011014",
                              "D000014777",
                              "D000018352",
                              "D000003333",
                              "D000030341",
                              "D000012327",
                              "D000008171",
                              "D000012140"
                        ],
                        "ConditionAncestorTerm": [
                              "Respiratory Tract Infections",
                              "Infections",
                              "Pneumonia, Viral",
                              "Pneumonia",
                              "Virus Diseases",
                              "Coronavirus Infections",
                              "Coronaviridae Infections",
                              "Nidovirales Infections",
                              "RNA Virus Infections",
                              "Lung Diseases",
                              "Respiratory Tract Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC01",
                              "BC08",
                              "All",
                              "BC23"
                        ],
                        "NCTId": [
                              "NCT05125562"
                        ]
                  },
                  {
                        "Rank": 4,
                        "BriefSummary": [
                              "A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle product, for the treatment of medically refractory ulcerative colitis"
                        ],
                        "BriefTitle": [
                              "Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis"
                        ],
                        "CentralContactEMail": [
                              "sascha@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Sascha Sengupta, MD"
                        ],
                        "CentralContactPhone": [
                              "512-387-3685"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "March 1, 2024"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Ulcerative Colitis"
                        ],
                        "ConditionAncestorId": [
                              "D000005759",
                              "D000005767",
                              "D000004066",
                              "D000003108",
                              "D000007410",
                              "D000010335",
                              "D000015212"
                        ],
                        "ConditionAncestorTerm": [
                              "Gastroenteritis",
                              "Gastrointestinal Diseases",
                              "Digestive System Diseases",
                              "Colonic Diseases",
                              "Intestinal Diseases",
                              "Pathologic Processes",
                              "Inflammatory Bowel Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC23",
                              "All",
                              "BC06"
                        ],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 5,
                        "BriefSummary": [
                              "Infusion Treatment Using Bone Marrow Mesenchymal Stem Cell (bmMSC) Derived Extracellular Vesicle Product, ExoFlo\u2122, for COVID-19 Associated ARDS (EXIT COVID-19), is currently being studied in Protocol DB-EF-PhaseII-001 in patients with COVID-19 associated moderate to severe Acute Respiratory Distress Syndrome (ARDS).\n\nThis expanded access protocol is an open-label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase II randomized controlled trial because they:\n\nDo not meet phase II eligibility criteria at current phase II sites.\nDo meet phase II eligibility criteria but cannot access phase II sites.\nDo not meet phase II eligibility criteria & cannot access phase II sites. \u2022"
                        ],
                        "BriefTitle": [
                              "A Global Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS"
                        ],
                        "CentralContactEMail": [
                              "hmoran@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Heidi Moran"
                        ],
                        "CentralContactPhone": [
                              "800-791-1021"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [],
                        "CompletionDateType": [],
                        "Condition": [
                              "Covid19",
                              "ARDS",
                              "Hypoxia",
                              "Cytokine Storm"
                        ],
                        "ConditionAncestorId": [
                              "D000012141",
                              "D000007239",
                              "D000011024",
                              "D000011014",
                              "D000014777",
                              "D000018352",
                              "D000003333",
                              "D000030341",
                              "D000012327",
                              "D000008171",
                              "D000012140",
                              "D000012818",
                              "D000018746",
                              "D000007249",
                              "D000010335",
                              "D000012769"
                        ],
                        "ConditionAncestorTerm": [
                              "Respiratory Tract Infections",
                              "Infections",
                              "Pneumonia, Viral",
                              "Pneumonia",
                              "Virus Diseases",
                              "Coronavirus Infections",
                              "Coronaviridae Infections",
                              "Nidovirales Infections",
                              "RNA Virus Infections",
                              "Lung Diseases",
                              "Respiratory Tract Diseases",
                              "Signs and Symptoms, Respiratory",
                              "Systemic Inflammatory Response Syndrome",
                              "Inflammation",
                              "Pathologic Processes",
                              "Shock"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC01",
                              "BC08",
                              "All",
                              "BC23"
                        ],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 6,
                        "BriefSummary": [
                              "This is a Phase I/II trial to evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EV), ExoFlo, as treatment for Post-Acute COVID-19 and Chronic Post-COVID-19 syndrome."
                        ],
                        "BriefTitle": [
                              "ExoFlo\u2122 Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome"
                        ],
                        "CentralContactEMail": [
                              "hmoran@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Heidi Moran"
                        ],
                        "CentralContactPhone": [
                              "800-791-1021"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "February 2023"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Covid19",
                              "Postviral Syndrome",
                              "Dyspnea"
                        ],
                        "ConditionAncestorId": [
                              "D000004194",
                              "D000010335",
                              "D000012141",
                              "D000007239",
                              "D000011024",
                              "D000011014",
                              "D000014777",
                              "D000018352",
                              "D000003333",
                              "D000030341",
                              "D000012327",
                              "D000008171",
                              "D000012140",
                              "D000012120",
                              "D000012818"
                        ],
                        "ConditionAncestorTerm": [
                              "Disease",
                              "Pathologic Processes",
                              "Respiratory Tract Infections",
                              "Infections",
                              "Pneumonia, Viral",
                              "Pneumonia",
                              "Virus Diseases",
                              "Coronavirus Infections",
                              "Coronaviridae Infections",
                              "Nidovirales Infections",
                              "RNA Virus Infections",
                              "Lung Diseases",
                              "Respiratory Tract Diseases",
                              "Respiration Disorders",
                              "Signs and Symptoms, Respiratory"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC01",
                              "BC08",
                              "All",
                              "BC23",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT05116761"
                        ]
                  },
                  {
                        "Rank": 7,
                        "BriefSummary": [
                              "Extracellular Vesicle Infusion as Early Goal Directed Therapy for COVID-19 related ARDS (EXTINGuish COVID-19) is a multicenter, double-blinded, placebo-controlled, randomized clinical trial to evaluate the efficacy of ExoFlo in treating moderate to severe ARDS caused by COVID-19."
                        ],
                        "BriefTitle": [
                              "Bone Marrow Mesenchymal Stem Cell Derived EVs for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS): A Phase III Clinical Trial"
                        ],
                        "CentralContactEMail": [
                              "hmoran@directbioloics.com"
                        ],
                        "CentralContactName": [
                              "Heidi Moran"
                        ],
                        "CentralContactPhone": [
                              "800-791-1021"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "July 3, 2023"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "COVID-19 Acute Respiratory Distress Syndrome"
                        ],
                        "ConditionAncestorId": [
                              "D000004194",
                              "D000010335",
                              "D000012141",
                              "D000007239",
                              "D000011024",
                              "D000011014",
                              "D000014777",
                              "D000018352",
                              "D000003333",
                              "D000030341",
                              "D000012327",
                              "D000008171",
                              "D000012140",
                              "D000012120",
                              "D000007235",
                              "D000007232",
                              "D000055370"
                        ],
                        "ConditionAncestorTerm": [
                              "Disease",
                              "Pathologic Processes",
                              "Respiratory Tract Infections",
                              "Infections",
                              "Pneumonia, Viral",
                              "Pneumonia",
                              "Virus Diseases",
                              "Coronavirus Infections",
                              "Coronaviridae Infections",
                              "Nidovirales Infections",
                              "RNA Virus Infections",
                              "Lung Diseases",
                              "Respiratory Tract Diseases",
                              "Respiration Disorders",
                              "Infant, Premature, Diseases",
                              "Infant, Newborn, Diseases",
                              "Lung Injury"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC01",
                              "BC08",
                              "All",
                              "BC23",
                              "BC16",
                              "BC26",
                              "BXS",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 8,
                        "BriefSummary": [
                              "Title:\n\nIntermediate Size Expanded Access for the Use of ExoFlo in the Treatment of Abdominal Solid Organ Transplant Rejection Patients who are in a Serious or Life-Threatening Condition and Have No Or Limited Reasonable Options.\n\nRunning Title:\n\nExoFlo for Organ Transplant Rejection\n\nPhase:\n\nExpanded Access Protocol\n\nMethodology:\n\nOpen Label\n\nProgram Duration:\n\nThis program is expected to be open for up to 5 years\n\nSubject Participation:\n\nEach patient will be followed after treatment for 6 months\n\nSingle or Multi-Site:\n\nSingle site\n\nObjectives:\n\nPrimary Endpoint: Safety and any adverse/serious adverse events\n\nSecondary Endpoints: Improvement in serum inflammatory markers and inflammation of solid abdominal organ\n\nProgram Population:\n\n20 patients who meet the criteria for Expanded Access as determined by the principal investigator and who do not otherwise qualify for an available clinical trial\n\nDiagnosis and Main Inclusion Criteria:\n\nPatients who are experiencing abdominal solid organ transplant rejection based on clinical and laboratory evaluation and who have exhausted conventional therapy\n\nStudy Product, Dose, Route, Regimen:\n\n15 mL of ExoFlo will be given intravenously in a total volume of 100 mL (mixed with 85 mL of normal saline) up to nine times over the course of 1 year.\n\nStatistics:\n\nDescriptive statistics"
                        ],
                        "BriefTitle": [
                              "Intermediate Size Expanded Access for the Use of ExoFlo in the Treatment of Abdominal Solid Organ Transplant Patients Who Are at Risk of Worsening Allograft Function With Conventional Immunosuppressive Therapy Alone"
                        ],
                        "CentralContactEMail": [
                              "sascha@directbiologics.com"
                        ],
                        "CentralContactName": [
                              "Sascha Sengupta, MD"
                        ],
                        "CentralContactPhone": [
                              "512-387-3685"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "December 2022"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Solid Organ Transplant Rejection",
                              "Organ Rejection Transplants",
                              "Organ Rejection"
                        ],
                        "ConditionAncestorId": [],
                        "ConditionAncestorTerm": [],
                        "ConditionBrowseBranchAbbrev": [],
                        "NCTId": [
                              "NCT05215288"
                        ]
                  },
                  {
                        "Rank": 9,
                        "BriefSummary": [
                              "To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients with severe COVID-19."
                        ],
                        "BriefTitle": [
                              "Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "May 22, 2021"
                        ],
                        "CompletionDateType": [
                              "Actual"
                        ],
                        "Condition": [
                              "Covid19",
                              "ARDS",
                              "Pneumonia, Viral"
                        ],
                        "ConditionAncestorId": [
                              "D000012141",
                              "D000007239",
                              "D000011014",
                              "D000014777",
                              "D000018352",
                              "D000003333",
                              "D000030341",
                              "D000012327",
                              "D000008171",
                              "D000012140"
                        ],
                        "ConditionAncestorTerm": [
                              "Respiratory Tract Infections",
                              "Infections",
                              "Pneumonia",
                              "Virus Diseases",
                              "Coronavirus Infections",
                              "Coronaviridae Infections",
                              "Nidovirales Infections",
                              "RNA Virus Infections",
                              "Lung Diseases",
                              "Respiratory Tract Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC01",
                              "BC08",
                              "All",
                              "BC23",
                              "BC16",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  }
            ]
      }
}